Magazine Article | May 22, 2018

Trump Unveils Drug Reforms: Rebates To PBMs At Risk

Source: Life Science Leader

By John McManus, The McManus Group

After months of delay and suspense, in a Rose Garden ceremony, President Trump and HHS Secretary Alex Azar announced a comprehensive approach to prescription drugs, which they claimed would address major challenges:

  1. high and rising drug and out-of-pocket costs
  2. seniors and government programs overpaying for drugs due to lack of negotiation tools
  3. foreign governments catching a free ride on industry innovation.

Trump and Azar’s speeches were accompanied by a blueprint that identified changes for immediate review and take-up, as well as a far-reaching exploration of hundreds of ideas intended to address pricing distortions that have arisen in the pharmaceutical supply chain and other government policies that hamper competition and effective negotiation.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: